We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+12.59%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$796M
AUM Growth
+$227M
Cap. Flow
+$285M
Cap. Flow %
35.75%
Top 10 Hldgs %
96.21%
Holding
14
New
1
Increased
–
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$321M

Top Sells

Rank Stock Value
1
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$11.5M
2
RPTX
Repare Therapeutics
RPTX
+$10.8M
3
ADCT icon
ADC Therapeutics
ADCT
+$9.32M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$4.7M
5
AUTL
Autolus Therapeutics
AUTL
+$355K

Sector Composition

Rank Sector Weight
1 Healthcare 95.63%
2 Miscellaneous 4.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$330M 41.43%
+7,913,887
New +$321M
HARP
2
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$81.6M 10.25%
389,842
– –
ITOS
3
DELISTED
iTeos Therapeutics
ITOS
$80.5M 10.12%
2,355,557
– –
TCRR
4
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$74.4M 9.35%
3,370,982
– –
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$63.5M 7.98%
2,069,749
-318,588
-13% -$10.8M
ONCR
6
DELISTED
Oncorus, Inc.
ONCR
$33.1M 4.16%
2,377,031
– –
TPTX
7
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$25.5M 3.2%
269,186
-39,500
-13% -$4.7M
GTHX
8
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$22.3M 2.8%
927,794
-496,000
-35% -$11.5M
EPZM
9
DELISTED
Epizyme, Inc
EPZM
$20.3M 2.55%
2,331,534
– –
MRUS
10
DELISTED
Merus
MRUS
$14.6M 1.84%
700,879
– –
YMAB
11
DELISTED
Y-mAbs Therapeutics
YMAB
$10.2M 1.28%
337,291
– –
ADCT icon
12
ADC Therapeutics
ADCT
$146M
$5.32M 0.67%
218,027
-321,621
-60% -$9.32M
AUTL
13
Autolus Therapeutics
AUTL
$623M
– –
-39,740
Closed -$355K

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2021 Portfolio in Review

As of Q1 2021, MPM BioImpact held 14 positions worth $796M, up 40% from $569M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

MPM BioImpact deployed $285M of net new capital in Q1 2021, opening 1 new position. Its largest new stake was Cullinan Oncology: 7,913,887 shares worth $330M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was G1 Therapeutics, Inc. Common Stock, an estimated $11.5M trimmed.

  • MPM BioImpact's largest Q1 2021 buy was Cullinan Oncology: 7,913,887 shares worth $330M.
  • MPM BioImpact's biggest Q1 2021 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $11.5M.
  • MPM BioImpact fully exited Autolus Therapeutics in Q1 2021, selling an estimated $355K.
  • MPM BioImpact's ten largest holdings make up 96% of its $796M portfolio in Q1 2021.
  • MPM BioImpact opened 1 new position and closed 1 in Q1 2021.
  • MPM BioImpact's portfolio value rose 40% quarter-over-quarter to $796M.

Based on MPM BioImpact's 13F filing for Q1 2021, filed 13 May 2021.